Figure 4.

Changes in total Sharp score in patients with active rheumatoid arthritis who were given one of two dosages of adalimumab or placebo. Reproduced with permission from John Wiley & Sons, Inc. [36]. © 2002 American College of Rheumatology

Schwartzman et al. Arthritis Res Ther 2004 6(Suppl 2):S3-S11   doi:10.1186/ar1013